Salute e Benessere

PharmaVentures Appoints Samara Ferguson as Vice President to Lead Pricing and…

Samara's consultancy experience also brings many years of insight across numerous therapy areas, where she rigorously pressure-tested market access and price potential, developed market access strategies, evidence generation plans, and bespoke real-world studies. Samara's consultancy experience also brings many years of insight across numerous therapy areas, where she rigorously pressure-tested market access and price potential, developed market access strategies, evidence generation plans…
PR Newswire
03/07/2025

Zelluna ASA - Grant of Share Options under Long-Term Incentive Program

Oslo, 3 July 2025:On the basis of the approval by the General Meeting on 29 April 2025 to authorize the Board of Directors of Zelluna ASA (the ‘Company’, OSE ticker “ZLNA”) to grant new shares to employees and board members under a long-term incentive program, the Board of Directors has resolved to issue share options to all employees in the Company.A total of 1,634,000 options for shares in the Company have been distributed amongst the employees and two board members. The number of...
Nasdaq GlobeNewswire
03/07/2025

Esaote presents at ECVS 2025 the new generation of veterinary MRI, Vet -MR…

"Putting our customers first is the driving force behind our innovation at Esaote," said Erminio Bassi, Esaote Vet Business Manager. "The Vet-MR Grande ELITE builds on the proven success of the Vet-MR Grande, bringing smarter technology, greater sustainability, and introducing a suite of innovations designed to elevate the standards of veterinary imaging, with the aim of delivering outstanding image quality, enabling clearer, more reliable diagnoses." "Putting our…
PR Newswire
03/07/2025

Sectra publishes Annual Report and Sustainability Report for 2024/2025

A summary of the financial year is also available on the website. The 2024/2025 financial year in brief summarizes highlights from our operations and a selection of financial performance measures. A summary of the financial year is also available on the website.The 2024/2025 financial year in briefsummarizes highlights from our operations and a selection of financial performance measures. This information constitutes information that Sectra AB (publ) is obliged to make public pursuant...
PR Newswire
03/07/2025

TikTok-Viral Snail Hydrogel Mask and New COSRX Launches on Sale for Amazon Prime…

With savings of up to 29%, the Prime Day event gives UK skincare shoppers the opportunity to discover COSRX's latest performance-driven formulas - from hydration and sun protection to barrier care - just in time for peak summer skincare season. With savings of up to 29%, the Prime Day event gives UK skincare shoppers the opportunity to discover COSRX's latest performance-driven formulas - from hydration and sun protection to barrier care - just in time for peak summer skincare season. Shop...
PR Newswire
03/07/2025

ReCerf Receives its CE Mark, Advancing Access to Ceramic Hip Resurfacing Across…

ReCerf is the world's first commercially available ceramic HRA, first approved by Australia's Therapeutic Goods Administration in November 2024. Since its initial use in 2018, over 1,600 patients have received the device. Patient-reported outcomes are highly positive, and the revision rate remains very low up to six years. ReCerf is the world's first commercially available ceramic HRA, first approved byAustralia'sTherapeutic Goods Administration inNovember 2024. Since its initial use in...
PR Newswire
03/07/2025

Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab…

Evfraxy® is authorised for the treatment of osteoporosis in men and postmenopausal women, the treatment of bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures or treatment of bone loss associated with long-term systemic glucocorticoid therapy in adults. Evfraxy® is authorised for the treatment of osteoporosis in men and postmenopausal women, the treatment of bone loss linked to hormone ablation in men with prostate cancer at increased risk of...
PR Newswire
03/07/2025

ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT Q2 2025

Revenue in Zinzino's sales markets increased by 61% in the second quarter of 2025 compared with the same period last year and amounted to SEK 776.1 (483.3) million. Total revenues in the Group increased by 56% in the second quarter and amounted to SEK 791.0 (507.0) million. Revenue in Zinzino's sales markets increased by 61% in the second quarter of 2025 compared with the same period last year and amounted toSEK 776.1(483.3) million. Total revenues in the Group increased by 56% in the...
PR Newswire
03/07/2025

EQT to acquire Europa Biosite, a distributor of life science products

EQT Healthcare Growth seeks to scale healthcare companies by building commercial muscle and expanding reach, building on EQT's three-decade track record in the healthcare sector. Europa Biosite will draw on this experience to expand its own-brand offering in biospecimens, continue its acquisition strategy to strengthen local market presence and expand to new geographies, and invest in new digital infrastructure. The Company is also set to benefit from EQT's track record in specialized…
PR Newswire
03/07/2025

Groundbreaking pan-European study by Alpharmaxim and Aston University harnesses…

Parkinson's is widely considered to be one of the greatest challenges in medicine. With no cure currently available, treatment options are limited not just by local availability, but also by underlying factors impacting prescribing decisions and habitual prescribing behaviours. In cases such as this, behavioural science holds the key to driving change. Parkinson's is widely considered to be one of the greatest challenges in medicine. With no cure currently available, treatment options are...
PR Newswire
03/07/2025

New research by Alpharmaxim applies behavioural science to identify and…

56 factors that influence prescribing behaviour were identified, categorised into patient, HCP or healthcare system groups, and mapped onto TDF (Theoretical Domains Framework) and COM-B (Capability, Opportunity, Motivation–Behaviour) models. 56 factors that influence prescribing behaviour were identified, categorised into patient, HCP or healthcare system groups, and mapped onto TDF (Theoretical Domains Framework) and COM-B (Capability, Opportunity, Motivation–Behaviour) models. Findings...
PR Newswire
03/07/2025

New President and CEO of Systemair

"The board is very pleased to present Robert Larsson as new President and CEO," says Gerald Engström, Chairman of the Board. "Robert has broad industrial and international experience and will, together with our organisation, develop Systemair further in our growth journey." "The board is very pleased to presentRobert Larssonas new President and CEO," says Gerald Engström, Chairman of the Board. "Robert has broad industrial and international experience and will…
PR Newswire
03/07/2025

Volta Labs Expands Presence in the Nordic Region with Callisto Placement at…

"NSC is proud to be the first lab in Norway—and across the Nordics—to adopt Volta's Callisto system," said Professor Kjetill S. Jakobsen, Head of the Norwegian Sequencing Centre and the Centre for Ecological and Evolutionary Synthesis (CEES). "We have deep expertise in long-read sequencing and are excited to adopt a novel platform that streamlines and scales our PacBio workflows. We have processed sample types that have spanned human, mammals, bird, fish, fungi, and plant species…
PR Newswire
03/07/2025

Novotech Earns Frost & Sullivan's 2025 Global Company of the Year Recognition…

The company stands apart in the global CRO landscape with its strategic emphasis on serving biotech clients, offering tailored clinical trial solutions across all phases of development. The company operates in more than 30 locations and has cultivated deep local insights across key clinical trial hubs, including Australia, South Korea, India, China, and the United States. Its ability to combine global standards with regional excellence makes Novotech a trusted partner for biotech sponsors…
PR Newswire
03/07/2025

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell…

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA 1Safety in GCA patients was consistent with known safety profile of Cosentyx® (secukinumab) 1Basel, July 03, 2025– Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx was evaluated in...
Nasdaq GlobeNewswire
03/07/2025

Neurizon Enters into Global License with Elanco to Accelerate Commercialisation…

This license agreement represents a critical inflection point for Neurizon, further strengthening the Company's strategic outlook for the development, manufacturing and potential future commercialisation of NUZ-001. It also significantly supports the Company's regulatory foundations, providing ongoing access to critical animal safety data and manufacturing data, key pillars required to support future clinical trials, potential regulatory approvals and global market entry. This license…
PR Newswire
03/07/2025

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study…

Key Takeaways from the Sleep Apnea Market Report Key Takeaways from the Sleep Apnea Market Report Discover more about sleep apnea treatment market segmentation @ Sleep Apnea Market Size Sleep Apnea Overview Sleep apnea is a common disorder in which breathing repeatedly stops and starts during sleep, leading to reduced oxygen levels and disrupted rest. These interruptions, often lasting 10–20 seconds and occurring up to 100 times per hour, typically prevent deep, restorative...
PR Newswire
02/07/2025

Inventiva announces the publication in Journal of Hepatology Reports on results…

Analysis of liver sinusoidal endothelial cells (“LSEC”) from screening and end of treatment biopsies in the Phase 2b NATIVE study showed evidence of LSEC capillarization in patients without MASH, and a further increased capillarization in patients with MASH In addition, in the subgroup of patients without MASH, there was higher LSEC capillarization in patients with MASLD than those with normal histologyLSEC capillarization observed in patients was strongly associated with liver...
Nasdaq GlobeNewswire
02/07/2025

Global Excel Acquires First Assistance to Strengthen Assistance Services and…

The partnership embodies Global Excel's commitment to delivering customer-centric assistance solutions that truly help people during their time of need. Together the teams are set to strengthen the region's assistance and claims offering, paving the way for a new era of growth and customer service excellence. The partnership embodies Global Excel's commitment to delivering customer-centric assistance solutions that truly help people during their time of need. Together the teams are set to...
PR Newswire
02/07/2025

Soft Tissue Repair Market to Hit $20.52 Billion by 2030--Driven by Regenerative…

The global soft tissue repair market, valued at US$15.12 billion in 2024, stood at US$15.96 billion in 2025 and is projected to advance at a resilient CAGR of 5.1% from 2025 to 2030, culminating in a forecasted valuation of US$20.52 billion by the end of the period. Behind this steady climb is a confluence of rising sports injuries, aging demographics, and an industry-wide shift toward minimally invasive and regenerative solutions. For C-suite executives, this signals more than just a medical…
PR Newswire
02/07/2025

Flavor and Fragrance Market to Hit USD 37.5 Billion by 2031 Amid Surge in…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-22F6638/Global_Flavor_and_Fragrance_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-22F6638/Global_Flavor_and_Fragrance_Market Major Factors Driving the Growth of Flavor and Fragrance Sales Market: The flavor and fragrance sales market continues to experience robust growth, driven by evolving consumer preferences, product innovation, and sectoral expansion across...
PR Newswire
02/07/2025

Nagish Joins WAWABILITY to Champion Communication Access at Groundbreaking ADA…

Tomer Aharoni, CEO and co-founder of Nagish, joins a lineup full of speakers who are shaping the future of accessibility, including innovators and legislators. Tomer's panel during the event, "Design, Capital, Impact. The Future of Disability Startup," will discuss the amazing things that happen when investor discipline meets inclusive design and ecosystem strategy. From mentorship and accelerators to investor-readiness and design rigor, this session will outline what it takes to build…
PR Newswire
02/07/2025

Moon Surgical Receives FDA Clearance for Maestro™ Connectivity and Predetermined…

"Connectivity unlocks a new layer of value for our customers," said Anne Osdoit, CEO of Moon Surgical. "With Maestro Insights, surgical teams gain a clearer understanding of their practice, and hospitals gain the tools to better manage and scale their surgical services. It's the next step in making data-driven surgery a practical reality." "Connectivity unlocks a new layer of value for our customers," said Anne Osdoit, CEO of Moon Surgical. "With Maestro…
PR Newswire
02/07/2025

mAbxience Announces European Commission Approval of Denosumab Biosimilars

Denbrayce®, referencing Amgen's Xgeva®, is indicated for the prevention of skeletal-related events in adults with advanced malignancies involving bone, as well as for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone. Izamby®, referencing Amgen's Prolia®, is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, a condition that causes bones to become weak and more prone to breaking...
PR Newswire
02/07/2025
Altri  Comunicati